CTLA4 and breast carcinoma: We previously generated two novel anti-CTLA-4 and PD-L1 mAbs, named ID-1 and PD-L1_1, respectively [32,33,34,35], and we used them in this study to test their effects as single agents or in combination on NK cells- or Pan T cells-enriched populations, co-cultured with TNBC or non-TNBC breast cancer cell lines, in comparison with the mAbs currently approved for clinical use, such as ipilimumab and atezolizumab.